Alexion Pharmaceuticals (ALXN)
$102.21 2.96 (2.98%)
14:05 EDT ALXN Stock Quote Delayed 15 Minutes
Previous Close -
Market Cap 22.74B
PE Ratio 43.87
Volume (Avg. Vol.) 1.48M
Day's Range 98.73 - 103.14
52-Week Range 92.56 - 141.86
Dividend & Yield N/A (N/A)
ALXN Stock Predictions, Articles, and Alexion Pharmaceuticals News
- From InvestorPlace
- From the Web
Eli Lilly, Alexion and AbbVie are just some of the top healthcare stocks to buy here, now that disappointing news has driven them to cheap prices.
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Expedia, Alexion and DowDuPont are just some of the stocks to buy to overcome the marketwide lethargy that takes shape this time of year.
These 10 smart money stocks to buy have significant support from top analysts. Here's why each should help you flourish throughout the rest of the year.
With stocks trading at record levels, it can be difficult to identify the best stocks to buy now. Here are 10 picks that the experts have faith in.
Here are some stocks trading near their 52-week high levels with potential to scale higher. Compare Brokers....
Stock charts of Express Scripts, Ventas and Alexion Pharmaceuticals are shaping up as your best bets as the week nears its end.
These 7 stock picks all boast support from the Street's top analysts. If you are looking to actually make money these are the stocks I recommend snapping up now. Here I also include price targets from the Street so you can see the kind of growth potential these gems have in store.
Yes the market is tricky right now. But Goldman Sachs has a report on stocks with the potential to explode. Here I single out the stocks with a 'Strong Buy' analyst consensus and see just why they are so compelling.
Alexion stock has come under fire lately, but the company has a promising pipeline of orphan drugs that could prod others to consider a takeover.
Alexion Pharmaceuticals (ALXN) stock was up today on positive results for a recent Phase 3 clinical study for the drug ALXN1210.
The Street's best analysts of 2017 (according to TipRanks) provide us with these 10 compelling investing opportunities.
Biotech's luck is changing as the trend looks to be upward and outward for the biotech stocks. These are the five to watch.
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) is a $26.3 billion in market value component of the Biotechnology GICS industry group where The current Portfolio Grader ranking for ALXN puts it 207 among the 349 companies in this industry group, which is a below-average position. ALXN is ranked in the third quartile of the sector with a ranking of 480 among the 785 companies in the sector and number 3,109 in the 5000 company Portfolio Grader company universe.
From Market News Video
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Alexion Pharmaceuticals Inc. (ALXN), where a total volume of 12,727 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares)..
From Talk Markets
From Analyst Ratings
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report), with a price target of $170.00. The company’s shares closed last Monday at $99.58, close to its 52-week low of $92.56. According to TipRanks.com, Harrison is a 4-star analyst with an average return of
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!